• Investors may be wondering whether Haemonetics at US$58.46 is starting to look interesting on value, or if the market is still unsure what it is worth.
• The stock has returned 6.4% over the last 7 days, while the 30 day and year to date returns are an 8.8% decline and a 26.9% decline. The 1 year return is a 0.8% decline and the 3 year and 5 year returns are a 30.2% and 49.9% decline.
• These mixed returns have kept attention on how the market is pricing Haemonetics and what is driving investor sentiment. Ongoing coverage of the company keeps valuation front and center for readers who want a consistent reference point, regardless of short term news flow.
• Haemonetics currently has a valuation score of 6/6. Next up is a look at how different valuation methods line up on the stock and how a broader perspective at the end of this article can help put those numbers in context.

Haemonetics delivered -0.8% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Approach 1: Haemonetics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting the cash it could generate in the future and then discounting those cash flows back to today.

For Haemonetics, the latest twelve month Free Cash Flow is about $304.0 million. The model being used is a 2 Stage Free Cash Flow to Equity approach that starts with analyst inputs and then extends them using Simply Wall St extrapolations. For example, one analyst estimate points to Free Cash Flow of $179 million in 2026 and $290 million in 2027, with Simply Wall St projections of around $277 million by 2028 and just under $299 million by 2035.

When all of those projected cash flows are discounted back using this model, the estimated intrinsic value for Haemonetics comes out at $90.13 per share. Compared with the recent share price of about $58.46, this suggests the stock is roughly 35.1% below this DCF estimate. This indicates a meaningful gap between the modelled value and where the market is pricing the shares today.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Haemonetics is undervalued by 35.1%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Haemonetics.

Approach 2: Haemonetics Price vs Earnings

For a profitable company like Haemonetics, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of earnings. It ties the share price directly to current profitability, so you can compare it across time and against other companies in the same space.

What counts as a "normal" or "fair" P/E often reflects a mix of growth expectations and risk. Higher expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty can lead to a lower one.

Haemonetics is currently trading on a P/E of 15.5x, compared with the Medical Equipment industry average of about 26.7x and a peer group average of 25.2x. Simply Wall St also provides a Fair Ratio of 21.4x, which represents the P/E that might be expected after considering factors such as earnings growth, industry, profit margin, market cap and company specific risks.

The Fair Ratio is more tailored than a simple peer or industry comparison because it attempts to adjust for those company specific characteristics rather than treating all firms as identical. With Haemonetics on 15.5x versus a Fair Ratio of 21.4x, the shares appear undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Haemonetics Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives let you attach a clear story about Haemonetics to the numbers by linking what you believe about its future revenue, earnings and margins to a financial forecast and then to a fair value that you can compare with the current price.

On Simply Wall St, within the Community page used by millions of investors, you can pick or create a Haemonetics Narrative that fits your view. For example, you might choose a cautious case that aligns with a Fair Value of US$70 based on slower growth and lower margins, or an optimistic case closer to US$108 that assumes stronger growth and higher profitability. The platform will keep that Narrative updated as fresh news or earnings are added so your decisions stay anchored to a living, numbers backed story rather than a static snapshot.

Do you think there's more to the story for Haemonetics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.